Diabetes Mellitus, Type 1 Clinical Trial
Official title:
Mini-Dose Glucagon to Treat Fasting-induced Hypoglycemia During Ramadan
Verified date | July 2021 |
Source | Qassim University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study aimed to develop a new approach for the treatment of fasting induced hypoglycemia during ramadan using mini-dose glucagon.
Status | Completed |
Enrollment | 20 |
Est. completion date | August 15, 2019 |
Est. primary completion date | June 10, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 64 Years |
Eligibility | Inclusion Criteria: 1. Clinical diagnosis of T1DM using daily insulin 2. 18.0 to < 65.0 years of age with body mass index 20.0 to <35.0 kg/m2. 3. Having diabetes for =2.0 years 4. HbA1c <8.5% 5. Has a smart phone with access to the internet and welling to upload data during the study period. 6. Welling to wear a devise such as continuous glucose monitor =6 days/week. 7. Females, not currently known to be pregnant 8. In good general health as evaluated by investigator based on available clinical data 9. Willing to comply to the protocol requirements for the duration of the study Exclusion Criteria: 1. Any history of more than one severe hypoglycemic episode (need assistance by third party) in the past 12 months 2. Any history of more than one episode of diabetic ketoacidosis in the past 12 months 3. Female pregnant or planning to get pregnant. 4. Use of any of the following medications: oral hypoglycemic agents, systemic corticosteroids or beta-blocker, theophylline, beta-adrenergic agonists, 1st generation anticholinergic drugs. 5. History of hypersensitivity to glucagon or severe hypersensitivity reactions (such as angioedema) to any other medications 6. History of uncontrolled hypertension (systolic BP >160 mmHg or diastolic BP >100 mmHg) 7. History of seizure disorder. 8. Presence of any of conditions based on judgment of the investigator that could affect or interfere with the response, absorption, metabolism or execration of glucagon. 9. Currently following any kind of weight-loss diet 10. Currently participation in another clinical trials |
Country | Name | City | State |
---|---|---|---|
Saudi Arabia | Qassim University | Buraydah |
Lead Sponsor | Collaborator |
---|---|
Qassim University |
Saudi Arabia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Changes in glucose values from baseline to 30 minute | The change in blood glucose from baseline to 30 minute following treatment of hypoglycemic events | 30 minutes | |
Secondary | Events approached 100 mg/dL or increased by 30 mg/dL | During the first hour following each hypoglycemic event (BG 50-69 mg/dL), the investigators will record the events approached 100 mg/dL or increased by 30 mg/dL | 60 Minutes | |
Secondary | Treatment success from first dose | During the first hour following each hypoglycemic event (BG 50-69 mg/dL), the investigators will record the events with blood glucose concentration =50 mg/dl 15 minute AND =70 mg/dl 30 minute after the initial treatment of a hypoglycemic event | 60 Minutes | |
Secondary | Mean Glucose Value, during hypoglycemia event by CGM | During the first hour following each hypoglycemic event (BG 50-69 mg/dL), the investigators will calculate the mean glucose value from CGM data | 60 Minutes | |
Secondary | Time in Range, during hypoglycemia event by CGM | During the first hour following each hypoglycemic event (BG 50-69 mg/dL), the investigators will calculate the percentage of time in range 70-180 mg/dL from CGM data. | 60 Minutes | |
Secondary | Time spend below 70 mg/dL, during hypoglycemia event by CGM | During the first hour following each hypoglycemic event (BG 50-69 mg/dL), the investigators will calculate the percentage of time <70 mg/dL from CGM data. | 60 Minutes | |
Secondary | Minimum Glucose, during hypoglycemia event by CGM | During the first two hour following each hypoglycemic event (BG 50-69 mg/dL), the investigators will record the minimum glucose value from CGM data. | 60 Minutes | |
Secondary | Maximum Glucose, during hypoglycemia event by CGM | During the first two hour following each hypoglycemic event (BG 50-69 mg/dL), the investigators will record the maximum glucose value from CGM data. | 60 Minutes | |
Secondary | Mean Glucose Value, during hypoglycemia event by CGM | During the first two hour following each hypoglycemic event (BG 50-69 mg/dL), the investigators will calculate the mean glucose value from CGM data | 120 Minutes | |
Secondary | Time in Range, during hypoglycemia event by CGM | During the first two hour following each hypoglycemic event (BG 50-69 mg/dL), the investigators will calculate the percentage of time in range 70-180 mg/dL from CGM data | 120 Minutes | |
Secondary | Time spend below 70 mg/dL, during hypoglycemia event by CGM | During the first two hour following each hypoglycemic event (BG 50-69 mg/dL), the investigators will calculate the percentage of time <70 mg/dL from CGM data | 120 Minutes | |
Secondary | Minimum Glucose, during hypoglycemia event by CGM | During the first two hour following each hypoglycemic event (BG 50-69 mg/dL), the investigators will record the minimum glucose value from CGM data. | 120 Minutes | |
Secondary | Maximum Glucose, during hypoglycemia event by CGM | During the first two hour following each hypoglycemic event (BG 50-69 mg/dL), the investigators will record the maximum glucose value from CGM data. | 120 Minutes | |
Secondary | The proportion of completion of fasts | The proportion of completion of fasts following treatment of hypoglycemic events | 2 Weeks | |
Secondary | Mean Glucose Value, by CGM | During the entire two weeks of intervention/comparator period, the investigators will calculate the mean glucose value from CGM data | 2 Weeks | |
Secondary | Time in Range, by CGM | During the entire two weeks of intervention/comparator period, the investigators will calculate the percentage of time in range 70-180 mg/dL from CGM data | 2 Weeks | |
Secondary | Time spend below 70 mg/dL, by CGM | During the entire two weeks of intervention/comparator period, the investigators will calculate the percentage of time <70 mg/dL from CGM data | 2 Weeks | |
Secondary | Time spend above 180 mg/dL, by CGM | During the entire two weeks of intervention/comparator period, the investigators will calculate the percentage of time >180 mg/dL from CGM data | 2 Weeks | |
Secondary | Time spend above 250 mg/dL, by CGM | During the entire two weeks of intervention/comparator period, the investigators will calculate the percentage of time >250 mg/dL from CGM data | 2 Weeks | |
Secondary | Coefficient of Variation, by CGM | During the entire two weeks of intervention/comparator period, the investigators will calculate the Coefficient of Variation from CGM data | 2 Weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04030091 -
Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus
|
Phase 4 | |
Terminated |
NCT03605329 -
Evaluation of the Severity of Cardiovascular Autonomic Neuropathy in Type 1 Diabetic Patients With OSAS
|
N/A | |
Completed |
NCT01696266 -
An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
|
||
Recruiting |
NCT06050642 -
Study of the Impact of PROximity Support for Patients With Type 1 DIABetes Treated With an Insulin Pump or Closed Loop.
|
N/A | |
Completed |
NCT05107544 -
Metabolic, Physical Fitness and Mental Health Effects of High Intensity Interval Training (HIIT) in Adolescents With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT04443153 -
Adapting Diabetes Treatment Expert Systems to Patient in Type 1 Diabetes
|
N/A | |
Completed |
NCT04521634 -
Glycaemic Variability in Acute Stroke
|
||
Completed |
NCT04569994 -
A Study to Look at the Safety of NNC0363-0845 in Healthy People and People With Type 1 Diabetes
|
Phase 1 | |
Completed |
NCT04089462 -
Effects of Frequency and Duration of Exercise in People With Type 1 Diabetes A Randomized Crossover Study
|
N/A | |
Completed |
NCT03143816 -
Study Comparing Prandial Insulin Aspart vs. Technosphere Insulin in Patients With Type 1 Diabetes on Multiple Daily Injections: Investigator-Initiated A Real-life Pilot Study-STAT Study
|
Phase 4 | |
Completed |
NCT01892319 -
An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
|
||
Recruiting |
NCT04039763 -
RT-CGM in Young Adults at Risk of DKA
|
N/A | |
Completed |
NCT04042207 -
Diabeloop for Highly Unstable Type 1 Diabetes
|
N/A | |
Not yet recruiting |
NCT06068205 -
COMPARATIVE ANALYSIS OF THE MORPHO-MECHANICAL PROPERTIES OF RED BLOOD CELLS EXTRACTED FROM DIABETIC PATIENTS WITH AND WITHOUT MICROVASCULAR COMPLICATIONS
|
||
Recruiting |
NCT05909800 -
Prolonged Remission Induced by Phenofibrate in Children Newly Diagnosed With Type 1 Diabetes.
|
Phase 2 | |
Active, not recruiting |
NCT04974528 -
Afrezza® INHALE-1 Study in Pediatrics
|
Phase 3 | |
Completed |
NCT04530292 -
Home Intervention and Social Precariousness in Childhood Diabetes
|
N/A | |
Completed |
NCT05428943 -
OPT101 in Type 1 Diabetes Patients
|
Phase 1 | |
Recruiting |
NCT03988764 -
Monogenic Diabetes Misdiagnosed as Type 1
|
||
Completed |
NCT05597605 -
The SHINE Study: Safety of Implant and Preliminary Performance of the SHINE SYSTEM in Diabetic Subjects
|
N/A |